AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca, in collaboration with Takeda, is conducting a Phase 2 clinical study titled ‘A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy.’ The study aims to assess the effectiveness and safety of TAK-341 in treating Multiple System Atrophy (MSA), a rare neurodegenerative disorder, over a 52-week period.
The intervention being tested is TAK-341, an intravenous drug designed to treat MSA. Participants will receive either TAK-341 or a placebo in 13 infusions over the course of the study.
The study employs a randomized, parallel assignment model with triple masking, meaning neither participants, care providers, nor investigators know who receives the drug or placebo. The primary goal is treatment-focused, aiming to measure changes in MSA symptoms using the Unified Multiple System Atrophy Rating Scale Part I.
The study began on November 9, 2022, with an estimated completion date in 2025. The last update was submitted on July 7, 2025. These timelines are crucial for tracking the study’s progress and anticipating results.
The outcome of this study could significantly impact AstraZeneca’s stock performance, as positive results may enhance investor confidence and market position in the neurodegenerative treatment sector. Competitors in this field will be closely monitoring these developments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.